source
- Alnylam defends its heart failure silencers after AstraZeneca's ATTR-CM trial missAstraZeneca reported that its experimental drug Wainua failed to meet its primary endpoints in a study of transthyretin amyloid cardiomyopathy (ATTR-CM). The setback raised concerns about the thera…
- FDA grants approval to Revolution Medicines' Rasonque for pancreatic cancerThe U.S. Food and Drug Administration has approved Rasonque, a new therapy from Revolution Medicines, for the treatment of pancreatic cancer. The decision follows data that showed the drug nearly…